Mechanisms of NLRP3 activation and pathology during neurodegeneration

Related Articles:

• The road ahead: 2022 January 20, 2022 # # # # The first post at the start of each year on the SoPD website tries to provide an overview of where things are in the search for ‘disease modifying’ therapies for Parkinson’s.  It is an exercise in managing expectations as well as discussing what research events are scheduled for the next year so that we can keep…
• The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
• The inflammasome field is heating up December 6, 2019   When a cell is sick or damaged it will send out signals alerting the immune system that something is wrong. If enough of these molecules are released, they will initate an “immune response” and this process is called inflammation. There is evidence in neurodegenerative conditions (like Parkinson’s and Alzheimer’s) that the inflammation process is involved, and inhibitors of particular…
• The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
• Does immunotherapy need therapy? June 12, 2021 # # # # Over the last decade, a large number of clinical trials involving immunotherapy have been conducted in the field of Alzheimer’s research. The overall success rate of these studies has not been encouraging. Immunotherapy involves artificially boosting the immune system so that it targets of particular pathogen – like a rogue protein in the case of Alzheimer’s…
• 2019: Year in review December 31, 2019   In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2019. Month-by-month we will briefly discuss some of the major pieces of research/announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies to any researchers who…
• Monthly Research Review – November 2019 November 30, 2019   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• Monthly research review: February 2020 February 29, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• Are we Enterin a new age? February 8, 2022   # # # # A Parkinson’s-focused biotech company called Enterin has had a very busy start to the new year, with publication of some interesting preclinical research and the announcement of Phase II clinical trial results. The clinical trial results met both the primary and secondary endpoints (the pre-determined measures of whether the treatment is effective) indicating a successful…
• ADepTing to the UCB-Novartis deal December 6, 2021 # # # # Alpha synuclein has long been viewed at “Public enemy #1” by the Parkinson’s research community. This sticky, abundant protein starts to cluster (or aggregate) in Parkinson’s. There have been several attempts to reduce levels of the protein floating around outside of cells (using “immunotherapy” approaches) But now clinical research is ramping up to determine if reducing…
• Monthy research review – December 2019 December 30, 2019   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• 'Sunday Morning Futures' on Biden's mental capacity, Jill Biden comparing Latinos to tacos August 1, 2022 This is a rush transcript from "Sunday Morning Futures" July 17, 2022. This copy may not be in its final form and may be updated.MARIA BARTIROMO, FOX NEWS ANCHOR: Good Sunday morning, everyone. Welcome to "Sunday Morning Futures." Thanks so much for joining us. I'm Maria Bartiromo. Today: weakness on the world stage. President Biden coming home from the Middle East…
• Mechanisms of NLRP3 activation and pathology during neurodegeneration August 4, 2022 Int J Biochem Cell Biol. 2022 Aug 1:106273. doi: 10.1016/j.biocel.2022.106273. Online ahead of print.ABSTRACTInflammasomes are multiprotein complexes that are mainly present in resident and infiltrating immune cells in the central nervous system. Inflammasomes function as intracellular sensors of immunometabolic stress, infection and changes in the local microenvironment. Inflammasome assembly in response to these 'danger signals', triggers recruitment and cluster-dependent activation…
• Mechanisms of NLRP3 activation and pathology during neurodegeneration August 4, 2022 Int J Biochem Cell Biol. 2022 Aug 1:106273. doi: 10.1016/j.biocel.2022.106273. Online ahead of print.ABSTRACTInflammasomes are multiprotein complexes that are mainly present in resident and infiltrating immune cells in the central nervous system. Inflammasomes function as intracellular sensors of immunometabolic stress, infection and changes in the local microenvironment. Inflammasome assembly in response to these 'danger signals', triggers recruitment and cluster-dependent activation…
• Mechanisms of NLRP3 activation and pathology during neurodegeneration August 4, 2022 Int J Biochem Cell Biol. 2022 Aug 1:106273. doi: 10.1016/j.biocel.2022.106273. Online ahead of print.ABSTRACTInflammasomes are multiprotein complexes that are mainly present in resident and infiltrating immune cells in the central nervous system. Inflammasomes function as intracellular sensors of immunometabolic stress, infection and changes in the local microenvironment. Inflammasome assembly in response to these 'danger signals', triggers recruitment and cluster-dependent activation…
• Mechanisms of NLRP3 activation and pathology during neurodegeneration August 4, 2022 Int J Biochem Cell Biol. 2022 Aug 1:106273. doi: 10.1016/j.biocel.2022.106273. Online ahead of print.ABSTRACTInflammasomes are multiprotein complexes that are mainly present in resident and infiltrating immune cells in the central nervous system. Inflammasomes function as intracellular sensors of immunometabolic stress, infection and changes in the local microenvironment. Inflammasome assembly in response to these 'danger signals', triggers recruitment and cluster-dependent activation…
• Mechanisms of NLRP3 activation and pathology during neurodegeneration August 4, 2022 Int J Biochem Cell Biol. 2022 Aug 1:106273. doi: 10.1016/j.biocel.2022.106273. Online ahead of print.ABSTRACTInflammasomes are multiprotein complexes that are mainly present in resident and infiltrating immune cells in the central nervous system. Inflammasomes function as intracellular sensors of immunometabolic stress, infection and changes in the local microenvironment. Inflammasome assembly in response to these 'danger signals', triggers recruitment and cluster-dependent activation…
• Natural (born) killers January 28, 2020   Today’s post starts with more of a biology lesson than usual, but it is important to understand where in the grand scheme of things a certain type of blood cell sits. That type of blood cell has a really cool name: Natural killer cells. Recently researchers at the University of Georgia (USA) published a report suggesting that natural killer…
• Monthly Research Review – November 2020 November 30, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
• Shining a light on Parkinson’s November 7, 2019   NOTE: The information in today’s post should not be considered an endorsement of PhotoPharmics or the treatment they are proposing. The author of this blog has had no communication with the company. The information in this post is provided because the author has been asked by readers to discuss it. In October 2018, at the annual International Movement Disorders…
• Monthly Research Review: January 2022 January 31, 2022 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during January 2022. The post is divided into 10 parts based on the type of research: Top 6 pieces of Parkinson’s news Articles of general interest Basic biology…
• AC Immune acquires assets of AFFiRiS July 30, 2021 # # # # Alpha synuclein is considered to be an influential factor in Parkinson’s. It is a protein that accumulates and clumps together inside certain nerve cells in many cases of Parkinson’s. Recently, clinical trials have attempted to target alpha synuclein that is floating around outside of cells. Some of the strategies focus on an approach called ‘immunotherapy’, which…